| EBITDA Margin: guided vs achieved | 27.10% achieved Guided 25.50%–26.50%, 2.3% above the top of the range |
|---|---|
| Management target | Revenue 20.0% FY27 |
| Revenue growth | Revenue rose 17.3% YoY to ₹4,338 Cr, driven by chronic therapies. |
|---|---|
| Margins | EBITDA margin expanded 210 bps YoY to 27.1% via operating leverage. |
| Demand visibility | Strong chronic demand; recovery noted in acute gastro and vitamins. |
| Management confidence | High; emphasizing structural outperformance against IPM and disciplined execution. |
Growth
Domestic revenue grew 14.8% YoY; volume growth of 6.7% significantly outperformed the market's 1.2%.
Outlook
Management aims for 50% chronic therapy share in 4-5 years, targeting 100-200 bps annual expansion.
Risks
Consumer health sluggishness in East/South India and increased effective tax rate following exemption expiry.
Last quarter's promises, checked
Delivered
- FY27 EBITDA margin 25.5–26.5% → 27.1% (= BEAT)
- BSV high-teens growth → BSV +34% (= BEAT)
- FY27 double-digit growth → domestic +14.8% (= BEAT)
Partly delivered
- Acquisition debt repaid by FY28 (0.9x Q1) → 0.6x post-repayment; FY28 not yet due (= PARTIAL)
Missed
- Consumer health high-single to double-digit from Q2 → 'muted', % not disclosed (= MISS)
Earnings Call Transcript filed with NSE, NSE: MANKIND. Summary written with AI assistance from the document.
Mankind Pharma Ltd: key numbers
- Share price
- ₹2,490.00
- Market cap
- ₹1,02,848 Cr
- Revenue (annual)
- ₹14,278 Cr
- Net profit (annual)
- ₹1,913 Cr
- P/E (TTM)
- 45.9×Sector 46.1×
- Promoter holding
- 72.62%-0.01% QoQ
- FII holding
- 9.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mankind Pharma Ltd
All →Mankind Pharma Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹4,338 Cr (+17.3% YoY), EBITDA ₹1,175 Cr (27.1% margin), PAT ₹716 Cr (+37.7%). Domestic ex-CH +15.9%, exports +32.7%, CH +1.2%.
Mankind Pharma Results Update
Mankind Pharma reported Q2 FY27 revenue of ₹4,338 Cr, up 17% YoY, and PAT of ₹716 Cr, up 38%. EBITDA margin improved 210 bps to 27.1%.
Mankind Pharma Acquisition
Mankind Pharma's board approved amalgamation of two wholly owned subsidiaries into the parent and a step-down subsidiary merger into MCPPL. Schemes require NCLT and shareholder approvals.
Mankind Pharma Q2 FY27 Results: Net Profit ₹716.1 Cr, Up 37.7% YoY
Mankind Pharma Ltd reported revenue from operations of ₹4,338 Cr (+17.3% YoY) and net profit of ₹716.1 Cr (+37.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹716.1 Cr · +37.7% YoY
Mankind Pharma Other Announcement
Mankind Pharma Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Mankind Pharma Debt & Borrowing: ₹1,400 Cr
Mankind Pharma has successfully completed the interest payment and full redemption of its Non-Convertible Debentures due on October 16, 2026.
- Value
- ₹1,400 Cr